Off-tumor IDO1 target engagements determine the cancer-immune set point and predict the immunotherapeutic efficacy

BACKGROUND: Indoleamine-2,3-dioxygenase 1 (IDO1) has been intensively pursued as a therapeutic target to reverse the immunosuppressive cancer-immune milieu and promote tumor elimination. However, recent failures of phase III clinical trials with IDO1 inhibitors involved in cancer immunotherapies hig...

Descripción completa

Detalles Bibliográficos
Autores principales: Xie, Lin, Hu, Kuan, Duo, Yanhong, Shimokawa, Takashi, Kumata, Katsushi, Zhang, Yiding, Jiang, Cuiping, Zhang, Lulu, Nengaki, Nobuki, Wakizaka, Hidekatsu, Cao, Yihai, Zhang, Ming-Rong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Immunotherapy Biomarkers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8237741/
https://www.ncbi.nlm.nih.gov/pubmed/34148865
http://dx.doi.org/10.1136/jitc-2021-002616

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8237741/
https://www.ncbi.nlm.nih.gov/pubmed/34148865
http://dx.doi.org/10.1136/jitc-2021-002616

Ejemplares similares